Stockwinners Market Radar for November 17, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:39 EST Avita Medical appoints David McIntyre CFO - AVITA Medical announced the appointment of David McIntyre as CFO effective November 18. McIntyre will assume responsibility for overseeing the global finance and investor relations functions and will be based in AVITA's Valencia office in California. Interim CFO Tim Rooney will continue in his role as AVITA Medical's Chief Administrative Officer with responsibility for global operations and supply chain management, program management, human resources, and information technology. Most recently, McIntyre served as a partner with Apple Tree Partners.

20:11 EST NIO Inc. appoints Wei Feng CFO - NIO Inc. announced that Wei Feng is joining the company as its new CFO, effective November 18. Prior to joining NIO, Feng served as managing director and head of the auto and auto parts research team at China International Capital Corporation.

15:11 EST Esperion presents pooled analyses from four Phase 3 bempedoic acid studies - Esperion announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American Heart Association, or AHA, Scientific Sessions in Philadelphia. Bempedoic acid is being developed as a convenient, once-daily, oral therapy for the treatment of patients with elevated low-density lipoprotein cholesterol added onto maximally tolerated statin therapy. Bempedoic acid and the bempedoic acid 180 mg + ezetimibe 10 mg fixed dose combination tablets' new drug applications are currently under regulatory review by the FDA and the marketing authorisation applications are currently under centralized review by the European Medicines Agency, or EMA. "We are very pleased with the pooled analyses from the Phase 3 LDL-C lowering clinical development program showing bempedoic acid not only lowered LDL-C by 25% but also reduced HbA1c by 0.19% in 1,134 patients with diabetes," said Tim Mayleben, CEO of Esperion. "These pooled analyses further support our confidence that bempedoic acid could be a convenient and important, oral, once-daily drug for the millions of patients on maximally tolerated statin therapy who need additional LDL-C lowering."

15:04 EST HP unanimously rejects unsolicited Xerox proposal - HP Inc. (HPQ) announced that its board has unanimously rejected the unsolicited proposal from Xerox Holdings Corporation (XRX) to acquire the company. The HP board sent a letter to Xerox CEO John Visentin, stating, "Our board of directors has reviewed and considered your unsolicited proposal dated November 5, 2019 at a meeting with our financial and legal advisors and has unanimously concluded that it significantly undervalues HP and is not in the best interests of HP shareholders. In reaching this determination, the board also considered the highly conditional and uncertain nature of the proposal, including the potential impact of outsized debt levels on the combined company's stock. We have great confidence in our strategy and our ability to execute to continue driving sustainable long-term value at HP. In addition, the board and management team continue to take actions to enhance shareholder value including the deployment of our strong balance sheet for increased repurchases of our significantly undervalued stock and for value-creating M&A. We recognize the potential benefits of consolidation, and we are open to exploring whether there is value to be created for HP shareholders through a potential combination with Xerox. However, as we have previously shared in connection with our prior requests for diligence, we have fundamental questions that need to be addressed in our diligence of Xerox. We note the decline of Xerox's revenue from $10.2B to $9.2B (on a trailing 12-month basis) since June 2018, which raises significant questions for us regarding the trajectory of your business and future prospects. In addition, we believe it is critical to engage in a rigorous analysis of the achievable synergies from a potential combination. With substantive engagement from Xerox management and access to diligence information on Xerox, we believe that we can quickly evaluate the merits of a potential transaction. We remain ready to engage with you to better understand your business and any value to be created from a combination."

13:11 EST Analysis shows Jardiance decreased risk of hospitalization for heart failure - A new interim analysis of three-year data from the EMPagliflozin compaRative effectIveness and SafEty, EMPRISE, real-world study on effectiveness shows that Jardiance was associated with a decreased risk of hospitalization for heart failure and a similar risk of non-fatal atherosclerotic cardiovascular events compared with DPP-4 inhibitors and GLP-1 receptor agonists. The interim analysis included 190,000 adults in the U.S. with type 2 diabetes with and without cardiovascular disease. The results were shared on behalf of Boehringer Ingelheim and Eli Lilly and Company (LLY) at the American Heart Association Scientific Sessions 2019 in Philadelphia.

13:05 EST Boeing, Biman announce order for two 787-9 Dreamliner jets - Boeing and Biman Bangladesh Airlines announced at the 2019 Dubai Airshow that the carrier is expanding its 787 Dreamliner fleet with two additional airplanes valued at $585M at list prices. The purchase - recorded in October as an unidentified order on Boeing's website - complements Biman's fleet of 787-8 jets with the larger and longer-range 787-9 variant.

13:01 EST Caladrius reports 'positive' results for CLBS16 from ESCaPE-CMD trial - Caladrius Biosciences presented results from the ESCaPE-CMD trial of Caladrius's autologous CD34+ cell therapy, CLBS16, at the American Heart Association Scientific Sessions 2019. Data showed highly statistically significant improvement in coronary flow reserve correlating with symptom relief for patients with coronary microvascular dysfunction after a single intracoronary injection of CLBS16. The results for patients who have completed the six-month follow-up to date were presented, with the results from the remaining patients expected by the end of 2019. "CLB16 represents a potential breakthrough for the treatment of CMD, a condition that affects millions in the U.S. and that disproportionately afflicts women. This is the first time that a therapy has shown the ability to durably increase coronary flow reserve and potentially reverse CMD after a single dose. These reported results clearly support the premise that manageable cell-based tissue regeneration is possible in patients with CMD," said David Mazzo, CEO of Caladrius. "The reported results from the ESCaPE-CMD trial bring us one step closer to realizing the promise of CD34+ cell therapy to augment microvasculature in the heart enabling the restoration of health rather than simply management of disease."

12:57 EST The Medicines Co's ORION-10 study of Inclisiran met primary, secondary endpoints - The Medicines Company announced detailed results from ORION-10, the second of three pivotal 18-month low-density lipoprotein cholesterol, or LDL-C, lowering Phase 3 clinical studies of inclisiran, an investigational twice-yearly therapy to reduce LDL-C and the first and only cholesterol-lowering treatment in the siRNA class. In ORION-10, twice-yearly dosing with inclisiran sodium 300 mg met all primary and secondary efficacy endpoints, was well-tolerated and again demonstrated an excellent safety profile. Full study results were presented during a late-breaking science session at the American Heart Association, or AHA, Scientific Sessions in Philadelphia. "Cumulative exposure to high LDL-C levels presents a significant risk of future heart attacks and strokes for millions of people, particularly those with ASCVD," said study principal investigator R. Scott Wright, M.D., Professor of Medicine, Consultant in Cardiology, Mayo Clinic in Rochester, Minnesota. "The data from ORION-10 show that inclisiran lowers LDL-C significantly and sustains reductions over a six-month period with a safety profile similar to placebo."

12:52 EST Canadian National receives strike notice from train conductor union - CN said that the Teamsters Canadian Rail Conference - Conductors, Trainpersons and Yardpersons, or TCRC-CTY, which represents approximately 3,200 CN employees who work as train conductors and railyard coordinators only in Canada, has given the company a 72-hour notice of its intention to strike as of 00:01 hours Eastern Standard Time on November 19. Rob Reilly, executive VP and COO of CN, said: "We continue to negotiate in good faith to reach a fair agreement before the strike deadline. In the spirit of protecting the Canadian economy, we have offered the union binding arbitration and they have declined. If a settlement cannot be reached this weekend, we will once again encourage the union leadership to accept binding arbitration as an alternative to disrupting the Canadian economy. We remain committed to constructive talks to reach an agreement without a work stoppage."

12:47 EST Bristol-Myers sees no further extension for Celgene notes due to merger closing - Bristol-Myers Squibb Company (BMY) announced that it currently expects there will be no further extension of the expiration date of the offers to exchange notes issued by Celgene Corporation (CELG) for up to $19.85B aggregate principal amount of new notes to be issued by Bristol-Myers Squibb Company and cash and the related consent solicitations being made by Bristol-Myers Squibb on behalf of Celgene to adopt certain proposed amendments to the indentures governing the Celgene notes. As previously announced, the exchange offers and consent solicitations are currently scheduled to expire on November 20. The closing of the merger is expected to occur on November 20. As a result, Bristol-Myers Squibb currently expects that there will be no further extension of the expiration date as it is anticipated that the merger will be completed on the expiration date. The settlement date for the exchange offers is expected to occur on November 22, 2019.